Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.7803
Oct 30 • 3:59 PM ET Dollar change-0.0499 Percentage change(-6.01%)
Aftermarket Close
0.7816
Aftermarket • 6:14 PM ET Dollar change+0.0013 Percentage change(0.17%)
Index
-
Market Cap
29.48M
Enterprise Value
-53.46M
Income
-93.46M
Sales
13.56M
Book/sh
2.98
Cash/sh
3.19
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
119
IPO
Feb 09, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
2.17
P/B
0.26
P/C
0.24
P/FCF
-
EV/EBITDA
-
EV/Sales
-3.94
Quick Ratio
4.50
Current Ratio
4.50
Debt/Eq
0.34
LT Debt/Eq
0.28
Option/Short
No / Yes
EPS (ttm)
-2.49
EPS next Y
-1.88
EPS next Q
-0.64
EPS this Y
-5.63%
EPS next Y
24.61%
EPS next 5Y
7.64%
EPS past 3/5Y
-26.57% -42.49%
Sales past 3/5Y
13.59% 219.15%
EPS Y/Y TTM
-5.97%
Sales Y/Y TTM
-59.84%
EPS Q/Q
-36.21%
Sales Q/Q
-103.02%
Insider Own
21.07%
Insider Trans
0.11%
Inst Own
16.30%
Inst Trans
-1.57%
ROA
-41.91%
ROE
-60.61%
ROIC
-64.88%
Gross Margin
61.92%
Oper. Margin
-741.58%
Profit Margin
-689.20%
SMA20
-11.17%
SMA50
-25.24%
SMA200
-39.67%
Trades
Shs Outstand
37.78M
Shs Float
29.82M
52W High
2.62 -70.26%
52W Low
0.75 4.04%
Volatility
11.22% 7.93%
ATR (14)
0.06
RSI (14)
31.15
Beta
0.73
Rel Volume
0.51
Avg Volume
153.18K
Volume
77,878
Perf Week
-3.14%
Perf Month
-29.38%
Perf Quarter
-35.51%
Perf Half Y
-43.86%
Perf YTD
-51.83%
Perf Year
-68.02%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
0.83
Price
0.78
Change %
-6.01%
Consensus
Strong Buy
Avg. Price Target
$7.00
Implied Upside
+797.1%
Analysts7incl. previous ratings
Rating Distribution6 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 07, 2026Resumed
CChardan Capital Markets
Buy$5+540.8%
May 07, 2024Initiated
HH.C. Wainwright
Buy$10+1,181.6%
May 02, 2024Downgrade
JPM logoJJP Morgan
Overweight → Neutral$16 → $6+668.9%
Mar 05, 2024Initiated
WFC logoWWells Fargo
Overweight$25+3,103.9%
Mar 05, 2024Initiated
TD logoTTD Cowen
Outperform
Mar 05, 2024Initiated
JPM logoJJP Morgan
Overweight$16+1,950.5%
Mar 05, 2024Initiated
JEF logoJJefferies
Buy$23+2,847.6%
Mar 05, 2024Initiated
CChardan Capital Markets
Buy$21+2,591.3%
Mar 05, 2024Initiated
BMO logoBBMO Capital Markets
Outperform$22+2,719.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reid LaurenceDirectorSep 09 '26Buy1.1720,00023,40120,000Sep 11 07:51 PM
Wein MatthewSee RemarksSep 08 '26Sale1.16358415126,133Sep 10 03:47 PM
Irish JianSee RemarksSep 08 '26Sale1.162,1402,479375,393Sep 10 03:40 PM
Wapnick PamelaChief Financial OfficerSep 08 '26Sale1.161,9112,214206,580Sep 10 03:34 PM
Wapnick PamelaChief Financial OfficerJun 05 '26Sale1.302,8843,746208,491Jun 10 11:23 AM
Irish JianSee RemarksJun 05 '26Sale1.303,7374,854377,533Jun 10 11:21 AM
Wein MatthewSee RemarksJun 05 '26Sale1.30558725126,491Jun 10 11:19 AM
Wapnick PamelaChief Financial OfficerMar 05 '26Sale1.601,5812,530187,375Mar 09 05:16 PM
Wein MatthewSee RemarksMar 05 '26Sale1.60482771114,549Mar 09 05:16 PM
Irish JianChief Executive OfficerMar 05 '26Sale1.601,6072,571333,770Mar 09 05:15 PM
Thomas Brian C.DirectorDec 05 '25Sale1.773,8306,7862,510,960Dec 08 01:56 PM
Wein MatthewSee RemarksDec 05 '25Sale1.77199353115,031Dec 08 01:51 PM
Wapnick PamelaChief Financial OfficerDec 05 '25Sale1.771,5762,793188,956Dec 08 01:49 PM
Irish JianChief Executive OfficerDec 05 '25Sale1.771,6022,839563,839Dec 08 01:38 PM
Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Ph.D.Dr. Jian Irish M.B.A.
Chief Financial OfficerMs. Pamela M. Wapnick M.B.A.
Gen-er-al Coun-selMr. Matthew L. Wein J.D.
Co-Founder & Member of Scientific Advisory BoardDr. Joseph Knowles M.D.
Senior Vice Pres-i-dent of Tech-ni-cal Devel-op-ment & Oper-a-tionsMr. Mark Leonard